Atezolizumab Combo Approaches EU Approval for Frontline TNBC

June 28, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC). The CHMP recommendation, which is for patients with a PD-L1 expression level ≥1%, is based on data from the phase III IMpassion130 … (leggi tutto)